Immunogenicity of Therapeutic Coagulation Proteins

The U.S. FDA has announced a two-day public workshop entitled “New Methods to Predict the Immunogenicity of Therapeutic Coagulation Proteins,” scheduled to be held on September 17 and 18 in Bethesda, Maryland. The purpose of the workshop is to discuss recent scientific progress in identifying the genetic determinants for an unwanted (immunogenic) immune response to therapeutic coagulation proteins, and to identify and discuss potential new methods to predict such immunogenicity.

The workshop has been planned in partnership with the National Heart, Lung and Blood Institute, National Institutes of Health (NIH), the NATIONAL HEMOPHILIA FOUNDATION, and the PLASMA PROTEIN THERAPEUTICS ASSOCIATION (PPTA).



Posted by Tim Sandle